l'impegno alla trasparenza dell'industria farmaceutica a pubblicare i dati degli studi anche quando sono negativi! A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in pa… https://t.co/iWtfPfD4Pd
Tyrosine kinase inhibitor (TKI) resistance limits their use, this Phase 1b #clinicaltrial measures safety & efficacy of alpelisib, a PI-3 kinase inhibitor, combined with TKI, imatinib, to treat gastrointestinal stromal tumors #BMCCancer 🔎 Read here:
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor https://t.co/WaEydYfhJY #hvhebron #onco [Text complet] @BMC_series
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor https://t.co/mqWw8SeHKK